Prson Gautam

List of Publications by Year
in descending order

32 papers	1,633 citations	394421 19 h-index	580821 25 g-index
36 all docs	36 docs citations	36 times ranked	3511 citing authors

#	Article	IF	Citations
1	Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Cancer Research, 2022, 82, 586-598.	0.9	27
2	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science Advances, 2021, 7, .	10.3	28
3	Multiâ€modal metaâ€analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor. Molecular Systems Biology, 2021, 17, e9526.	7.2	8
4	CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. Cancer Research, 2021, 81, 4319-4331.	0.9	26
5	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery, 2020, 10, 104-123.	9.4	131
6	Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects. Nature Communications, 2020, 11, 6136.	12.8	63
7	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports, 2020, 31, 107764.	6.4	69
8	Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer. Computational and Structural Biotechnology Journal, 2020, 18, 3819-3832.	4.1	6
9	A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. Communications Biology, 2020, 3, 42.	4.4	23
10	Multiobjective optimization identifies cancer-selective combination therapies. PLoS Computational Biology, 2020, 16, e1008538.	3.2	9
11	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
12	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
13	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
14	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
15	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
16	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
17	Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. Npj Systems Biology and Applications, 2019, 5, 20.	3.0	32
18	Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets. Cell Chemical Biology, 2019, 26, 970-979.e4.	5.2	34

#	Article	IF	Citations
19	Prediction of drug combination effects with a minimal set of experiments. Nature Machine Intelligence, 2019, 1, 568-577.	16.0	99
20	Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. Cell Chemical Biology, 2018, 25, 224-229.e2.	5.2	124
21	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology, 2018, 68, 949-963.	7.3	106
22	KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell, 2018, 34, 807-822.e7.	16.8	112
23	Consistency in drug response profiling. Nature, 2016, 540, E5-E6.	27.8	76
24	Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. Molecular Cancer, 2016, 15, 34.	19.2	57
25	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell, 2016, 29, 75-89.	16.8	191
26	Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening. Assay and Drug Development Technologies, 2015, 13, 456-465.	1.2	57
27	Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. Chemistry and Biology, 2015, 22, 1144-1155.	6.0	22
28	Endothelial destabilization by angiopoietin-2 via integrin Î²1 activation. Nature Communications, 2015, 6, 5962.	12.8	210
29	Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. ACS Chemical Biology, 2015, 10, 1939-1951.	3.4	58
30	Bioluminescent Cell-Based NAD(P)/NAD(P)H Assays for Rapid Dinucleotide Measurement and Inhibitor Screening. Assay and Drug Development Technologies, 2014, 12, 514-526.	1.2	23
31	Donor Simvastatin Treatment Prevents Ischemia-Reperfusion and Acute Kidney Injury by Preserving Microvascular Barrier Function. American Journal of Transplantation, 2013, 13, 2019-2034.	4.7	41
32	Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets. SSRN Electronic Journal, 0, , .	0.4	0